Bilayered Nanoparticle Substrates for CRS Biofilm Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic rhinosinusitis (CRS) is challenging to treat due to the presence of bacterial biofilms, particularly those formed by Pseudomonas aeruginosa, which reduce antibiotic efficacy and lead to recurrent infections, necessitating a local treatment method that avoids systemic side effects and promotes sustained drug release.
Innovation Solution
A bilayered substrate with biocompatible and biodegradable polymers incorporating nanoparticles of antibiotics like ciprofloxacin and azithromycin, designed for controlled, sustained release, reducing biofilm mass and inflammation by inhibiting interleukin-8 production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic antibiotic treatment is used to ensure sufficient antibiotic exposure for eradication of microorganisms, then the effectiveness of treatment is improved, but systemic side effects increase
Solution Approach 1:
The patent segments the antibiotic delivery system into multiple functional layers: a first layer containing nanoparticles with first bioactive agents (antibiotics) and a second layer with second bioactive agents. This segmentation allows localized delivery to the sinus cavity while avoiding systemic circulation, thus maintaining treatment effectiveness at the infection site while minimizing systemic side effects.
Solution Approach 2:
The patent implements local quality by creating a localized drug delivery system that releases antibiotics specifically at the site of infection (sinus cavity) rather than systemically. The bilayered substrate structure with different bioactive agents in each layer provides localized treatment, improving antibiotic concentration at the infection site while avoiding harmful systemic effects.
2Reliability
If long course of antibiotic therapy is administered to penetrate into biofilms, then the penetration effectiveness is improved, but the duration of treatment increases
Solution Approach 1:
The patent ensures continuous and sustained release of bioactive agents from the bilayered substrate over an extended period. The first layer releases first bioactive agents and the second layer releases second bioactive agents continuously, maintaining effective antibiotic concentrations at the infection site throughout the treatment duration without requiring multiple separate administrations.
Solution Approach 2:
The patent incorporates agents that enhance antimicrobial activity in advance within the substrate layers. The first and second bioactive agents are pre-positioned in their respective layers to work synergistically from the outset, improving biofilm penetration effectiveness before the full treatment duration begins.
3Reliability
If multiple drugs are combined into one delivery system to provide synergistic effects, then the therapeutic efficacy is improved, but the device complexity increases
Solution Approach 1:
The patent merges multiple drugs into a single integrated delivery system by incorporating both first bioactive agents (antibiotics) and second bioactive agents (enhancing agents) within the same bilayered substrate. This combination allows synergistic effects to occur while maintaining a unified, manageable device structure that can be implanted as a single unit.
Solution Approach 2:
The bilayered substrate serves multiple functions simultaneously: it delivers antibiotics from the first layer, releases enhancing agents from the second layer, provides structural support, and enables sustained release over time. This multi-functionality is achieved within a single device, improving therapeutic efficacy without proportionally increasing complexity.
4Reliability
If agents enhancing antimicrobial activity are added to reduce biofilms, then the anti-biofilm efficacy is improved, but the quantity of substances to be delivered increases
Solution Approach 1:
The patent applies local quality by placing different bioactive agents in different layers of the substrate. The first layer contains antibiotics for direct bacterial killing, while the second layer contains enhancing agents that modulate biofilm properties. This spatial differentiation allows each agent to be delivered at optimized concentrations for its specific function, improving anti-biofilm efficacy while managing the total drug load efficiently.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bilayered substrate effectively reduces biofilm formation and mass, enhances antibiotic efficacy, and minimizes systemic side effects, providing a promising treatment for CRS by ensuring prolonged antibiotic exposure and anti-inflammatory effects.
Implementation Method 1
the bioactive agents are released at a constant rate over a period of time
Implementation Method 2
the layers of the substrates disclosed herein include biocompatible and biodegradable polymers
Implementation Method 3
the substrates disclosed herein are useful for reducing the mass of biofilms and reducing or preventing inflammation by inhibiting the production of interleukin-8
Data Source
AI summary
Disclosed herein are bilayered substrates useful for treating infection and/or inflammation in a subject such as, for example, the upper respiratory system. In another aspect, the layers of the substrates disclosed herein include biocompatible and biodegradable polymers as well as one or more bioactive agents useful for treating infection and/or inflammation. In a further aspect, the layers of the substrate can contain nanoparticles incorporating the bioactive agents. In any one of the above aspects, the bioactive agents are released at a constant rate over a period of time. In still another aspect, the substrates disclosed herein are useful for reducing the mass of biofilms and reducing or preventing inflammation by inhibiting the production of interleukin-8.